|This Slide: #94 of 100|
Slide #94. Cesca Therapeutics Inc. (f/n/a ThermoGenesis Corp.) — TotipotentRX Corporation
Cesca Therapeutics Inc. (f/n/a ThermoGenesis Corp.) (NASDAQ:KOOL)
Cesca Therapeutics Inc. (f/n/a ThermoGenesis Corp.) ("Company") (Nasdaq:KOOL) today announced that it consummated the merger with TotipotentRX Corporation ("TotipotentRX") for approximately 12,490,800 shares of the Company's common stock, as contemplated by the previously announced Agreement and Plan of Reorganization (the "Merger Agreement").
Cesca Therapeutics is a regenerative medicine company engaged in developing, commercializing and marketing a range of automated technologies for cell-based therapeutics. Through its subsidary, ThermoGenesis Corp., Co. is developing the X-Series of devices and reagent kits as part of the CAR-TXpress platform.The initial X-Series products are for research use and/or non-commercial manufacturing of cell-based products for clinical research. Co. is also developing commercial manufacturing devices and reagent kits for cGMP manufacturing of CAR-T for drug developers. Co.'s X-Series Products includes X-LAB for cell isolation and X-BACS for cell purification.
Open the KOOL Page at The Online Investor »
Strong Buy (4.00 out of 4)
(ranked higher than approx. 89% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite